Anti-Rituximab (RITUXAN, MABTHERA) ELISA Assay Kit
The Anti-Rituximab (RITUXAN, MABTHERA) ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Sensitivity: +/-
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µL
Alternative Name: Rituxan, Mabthera
Assay Background
Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes. After binding to CD20, rituximab mediates B-cell lysis {or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity {CDC) and antibody dependent cell-mediated cytotoxicity (ADCC). Rituximab belongs to the immunoglobulin Gl (IgGl) sub-class, consisting of a murine variable region (Fab region) and a human constant region {Fe region). The Fab region has variable sections that define a specific target antigen, allowing the antibody to attract and secure its exclusive antigen, specifically the binding of rituximab (IgGl) to CD20 on pre-Band mature B lymphocytes. The Fe region is the tail end of the antibody that communicates with cell surface receptors to activate the immune system, in this case, a sequence of events leading to the depletion of circulating B lymphocytes by complement-dependent cell lysis, antibody-dependent cellular cytotoxicity, as well as apoptosis. Therapeutic drug monitoring (TDM) is the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient’s bloodstream, thereby optimizing individual dosage regimens. The indications for drug monitoring include efficacy, compliance, drug-drug interactions, toxicity avoidance, and therapy cessation monitoring. Additionally, TDM can help to identify problems with medication compliance among noncompliant patient cases.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Controls and samples (serum or plasma) are incubated in the microtiter plate coated with the drug rituximab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to rituximab antibodies captured by the drug rituximab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of rituximab antibodies in the sample or controls. The results can be evaluated with using cut-off value.
Related Products
Rituximab ELISA Assay Kit
Rituximab mAb-based ELISA Assay
Anti-Infliximab (Remicade) ELISA Assay Kit
